These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37758560)

  • 1. Predictors of Response Following Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Urothelial Bladder Cancer Using Molecular Profile: A Prospective Clinical Study.
    Elkarta A; Awadalla A; El-Hefnawy A; Mosbah A; Abolenein H; Shokeir A
    Clin Genitourin Cancer; 2024 Apr; 22(2):38-46.e1. PubMed ID: 37758560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
    BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer.
    Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A
    Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
    Abdelrahman I; Aboulkassem H; Elazab A; Abdallah AY; Ismail Y; Taher M
    J Egypt Natl Canc Inst; 2023 May; 35(1):13. PubMed ID: 37145329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
    Grivas P; Koshkin VS; Chu X; Cole S; Jain RK; Dreicer R; Cetnar JP; Sundi D; Gartrell BA; Galsky MD; Woo B; Li-Ning-Tapia E; Hahn NM; Carducci MA
    Eur Urol Oncol; 2024 Aug; 7(4):914-922. PubMed ID: 38155060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?
    Ghandour RA; Kusin S; Wong D; Meng X; Singla N; Freifeld Y; Bagrodia A; Margulis V; Sagalowsky A; Lotan Y; Woldu SL
    Urol Oncol; 2020 Sep; 38(9):736.e11-736.e18. PubMed ID: 32684514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
    Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
    Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
    Becker REN; Meyer AR; Brant A; Reese AC; Biles MJ; Harris KT; Netto G; Matoso A; Hoffman-Censits J; Hahn NM; Choi W; McConkey D; Pierorazio PM; Johnson MH; Schoenberg MP; Kates MR; Baras A; Bivalacqua TJ
    Eur Urol; 2021 Mar; 79(3):364-371. PubMed ID: 32814637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy.
    Regnier P; DE Luca V; Brunelle S; Sfumato P; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Durand M; Gravis G; Pignot G
    Minerva Urol Nephrol; 2021 Apr; 73(2):215-224. PubMed ID: 32083413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy.
    Nielsen N; Wrist Lam G; Fabrin K; Holt P; Thind PO; Jensen JB
    Scand J Urol; 2019 Aug; 53(4):213-216. PubMed ID: 31174449
    [No Abstract]   [Full Text] [Related]  

  • 14. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
    Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
    Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.
    Robins D; Matulay J; Lipsky M; Meyer A; Ghandour R; DeCastro G; Anderson C; Drake C; Benson M; McKiernan JM
    Urology; 2018 Jan; 111():116-121. PubMed ID: 29032239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience.
    Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
    BJU Int; 2019 Jun; 123(6):1011-1019. PubMed ID: 30623554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
    Kilari D; Iczkowski KA; Pandya C; Robin AJ; Messing EM; Guancial E; Kim ES
    Anticancer Res; 2016 Feb; 36(2):495-501. PubMed ID: 26851002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodynamic prediction of neoadjuvant chemotherapy response: Results from a prospective multicenter study of predictive accuracy among muscle-invasive bladder cancer patients.
    Laviana AA; Schiftan EG; Mashni JW; Large MC; Kaimakliotis HZ; Nolte DD; Turek JJ; An R; Morgan TA; Chang SS
    Urol Oncol; 2023 Jun; 41(6):295.e9-295.e17. PubMed ID: 36522279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
    Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
    Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    Guancial EA; Kilari D; Xiao GQ; Abu-Farsakh SH; Baran A; Messing EM; Kim ES
    PLoS One; 2016; 11(5):e0155503. PubMed ID: 27187160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.